

Alston & Bird LLP

Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
(704) 444-1000
Fax (704) 444-1111

September 14, 2011

Certificate of Correction Branch
P.O. Box 1450
Alexandria, VA 22313-1450

ATTN: Ms. Marietta Joyce

Re: United States Patent for *C-Terminally Truncated Interferon Alpha Variants*
Application No. 10/574,046; Filed April 16, 2004
Patent No. 7,959,910; Issued June 14, 2011
Our File 040989/309915

Ms. Joyce:

It is respectfully requested that a Certificate of Correction be issued for the above-identified patent in accordance with 37 C.F.R. §1.323. This request is made in order to correct the mistakes incurred by Applicants.

The mistakes appearing in the patent are set forth on the Certificate of Correction e-filed herewith. The \$100.00 fee was paid during e-filing.

Applicants note that U.S. Application No. 10/574,046 is a national-stage application based on International Application No. PCT/US2004/011965, filed April 16, 2004. This international application claimed priority to U.S. Application No. 10/675,011, filed September 30, 2003. At the time of national-phase entry of this international application into the U.S. Designated/Elected Office on March 29, 2006, Applicants concurrently filed an initial Application Data Sheet, wherein Applicants in good faith claimed priority to U.S. Application No. 10/675,011, filed on September 30, 2003.

As evidence of Applicants' specific reference to U.S. Application No. 10/675,011, as a priority document for the above-identified patent, Applicants attach at the close of this letter the following documentation:


- (1) Copy of the coversheet for the published international application, WO 2005/035767 A1, wherein the claim for priority appears in the field for INID Code (30) (1 page);

Certificate of Correction Branch
ATTN: Ms. Marietta Joyce
U.S. Application No. 10/574,046
U.S. Patent No. 7,959,910; Issued June 14, 2011
September 14, 2011
Page 2

- (2) Copy of the U.S. Patent and Trademark Office transmittal of priority document form dated July 28, 2004, received by the World Intellectual Property Office (WIPO) on August 2, 2004, identifying U.S. Application No. 10/675,011, filed September 30, 2003, as the priority document being submitted in compliance with Rule 17.1(a) or (b) in connection with International Application No. PCT/US2004/011965 (1 page);
- (3) Copy of the PCT Notification Concerning Submission or Transmittal of Priority Document, mailed August 26, 2004, confirming the priority document, U.S. Application No. 10/675,011, had been received by the International Bureau of WIPO (1 page); and
- (4) Copy of the initial Application Data Sheet for the above-identified patent application, with the U.S. Patent and Trademark Office (PCT/PTO) "Date Received" stamp affixed thereon, showing a receipt date of March 29, 2006 (4 pages), wherein the specific claim for priority to U.S. Application No. 10/675,011 is set forth on page 3 of this document.

Applicants submit that the specific claim for priority to U.S. Application No. 10/675,011 was made in good faith at national-phase entry, in keeping with the claim for priority as made in International Application No. PCT/US2004/011965. It is believed that the printing error occurred because of the data entry field on the Application Data Sheet in which the priority claim was made. As this priority claim was made in good faith, and was carried over from International Application No. PCT/US2004/011965, Applicants respectfully request the issuance of a Certificate of Correction in order include the specific reference to U.S. Application No. 10/675,011, as a priority document in the field for INID Code (60), as noted on the Certificate of Correction e-filed herewith.

Respectfully submitted,


Leslie T. Henry
Registration No. 45,714

LTH/mlc
Attachments

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 April 2005 (21.04.2005)

PCT


(10) International Publication Number
WO 2005/035767 A1

- (51) International Patent Classification⁷: C12N 15/82, (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, IL, ID, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/US2004/011965
- (22) International Filing Date: 16 April 2004 (16.04.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 10/675,011 30 September 2003 (30.09.2003) US
- (71) Applicant (for all designated States except US): BIOLEX, INC. [US/US]; 158 Credle Street, Pittsboro, NC 27312 (US).
- (72) Inventors; and
(75) Inventors/Applicants (for US only): DICKEY, Lynn [US/US]; 111 Buckden Place, Cary, NC 27511 (US). GASDASKA, John [US/US]; 102 Lisa Drive, Carrboro, NC 27510 (US). COX, Kevin [US/US]; 1916 Sunset Drive, Raleigh, NC 27608 (US).
- (74) Agents: COULTER, Kathryn, L. et al.; Alston & Bird LLP, Bank of America Plaza, Suite 4000, 101 South Tryon Street, Charlotte, NC 28280-4000 (US).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ALPHA INTERFERON VARIANTS

(57) Abstract: The present invention provides biologically active variants of human α -2b-interferon. The variants contain carboxy terminus truncations when compared with the amino acid sequence of full-length human α -2b-interferon. It is the novel finding of the present invention that these truncated variants have the biological activity of full-length human α -2b-interferon. The invention encompasses these biologically active variant α -interferons, as well as polynucleotides encoding these interferons. Expression cassettes comprising these polynucleotides and host cells comprising the expression cassettes are also provided. The invention also provides compositions comprising variant α -interferon polypeptides and a pharmaceutically acceptable carrier.

WO 2005/035767 A1



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office


July 28, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE.

APPLICATION NUMBER: 10/675,011

FILING DATE: September 30, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/11965



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



N. Williams
N. WILLIAMS
Certifying Officer

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Baeck + F

PATENT COOPERATION TREATY

PCT

ALSTON & BIRD

RECEIVED
9-8-04NOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU


To:

COULTER, Kathryn, L.
Alston & Bird LLP
Bank of America Plaza
Suite 4000
101 South Tryon Street
Charlotte, NC 28280-4000
United States of America

Date of mailing (day/month/year) 26 August 2004 (26.08.2004)	
Applicant's or agent's file reference 40989/273797	IMPORTANT NOTIFICATION
International application No. PCT/US2004/011965	International filing date (day/month/year) 16 April 2004 (16.04.2004)
International publication date (day/month/year) Not yet published	Priority date (day/month/year) 30 September 2003 (30.09.2003)
Applicant BIOLEX, INC. et al	

- By means of this Form, which replaces any previously issued notification concerning submission or transmittal of priority documents, the applicant is hereby notified of the date of receipt by the International Bureau of the priority document(s) relating to all earlier application(s) whose priority is claimed. Unless otherwise indicated by the letters "NR", in the right-hand column or by an asterisk appearing next to a date of receipt, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
- (If applicable) The letters "NR" appearing in the right-hand column denote a priority document which, on the date of mailing of this Form, had not yet been received by the International Bureau under Rule 17.1(a) or (b). Where, under Rule 17.1(a), the priority document must be submitted by the applicant to the receiving Office or the International Bureau, but the applicant fails to submit the priority document within the applicable time limit under that Rule, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
- (If applicable) An asterisk(*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b) (the priority document was received after the time limit prescribed in Rule 17.1(a) or the request to prepare and transmit the priority document was submitted to the receiving Office after the applicable time limit under Rule 17.1(b)). Even though the priority document was not furnished in compliance with Rule 17.1(a) or (b), the International Bureau will nevertheless transmit a copy of the document to the designated Offices, for their consideration. In case such a copy is not accepted by the designated Office as priority document, Rule 17.1(c) provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date	Priority application No.	Country or regional Office or PCT receiving Office	Date of receipt of priority document
30 Sept 2003 (30.09.2003)	10/675,011	US	✓ 02 Augu 2004 (02.08.2004)



The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No. (41-22) 338.87.40	Authorized officer Ana MENA VALENCIA Telephone No. (41-22) 338 8665
--	---

IAP5 Rec'd PCT/PTO 29 MAR 2006

Application Data Sheet**Application Information**

Application Type::	Regular
Subject Matter::	Utility
Suggested classification::	NONE
Suggested Group Art Unit::	NONE
CD-ROM or CD-R?::	None
Number of CD disks::	0
Number of copies of CDs::	0
Sequence submission?::	Paper
Computer Readable Form (CRF)?::	YES
Number of copies of CRF::	1
Title::	ALPHA INTERFERON VARIANTS
Attorney Docket Number::	040989/309915
Request for Early Publication?::	No
Request for Non-Publication?::	No
Suggested Drawing Figure::	NONE
Total Drawing Sheets::	2 (transmitted with International Application)
Small Entity::	Yes
Petition Included?::	No
Petition Type::	NONE
Licensed US Govt. Agency::	NO
Contract or Grant Numbers::	NONE
Secrecy Order in Parent Appl.?::	No

Applicant Information

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: Lynn
Family Name:: Dickey
Name Suffix::
City of Residence:: Cary
State or Province of Residence:: NC
Country of Residence:: US
Street of mailing address:: 111 Buckden Place
City of mailing address:: Cary
State or Province of mailing address:: NC
Country of mailing address:: US
Postal or Zip Code of mailing address:: 27511

Applicant Authority Type:: Inventor
Primary Citizenship Country:: US
Status:: Full Capacity
Given Name:: John
Family Name:: Gasdaska
Name Suffix::
City of Residence:: Carrboro
State or Province of Residence:: NC
Country of Residence:: US
Street of mailing address:: 102 Lisa Drive
City of mailing address:: Carrboro
State or Province of mailing address:: NC
Country of mailing address:: US
Postal or Zip Code of mailing address:: 27510

Applicant Authority Type:: Inventor
 Primary Citizenship Country:: US
 Status:: Full Capacity
 Given Name:: Kevin
 Family Name:: Cox
 Name Suffix::
 City of Residence:: Raleigh
 State or Province of Residence:: NC
 Country of Residence:: US
 Street of mailing address:: 1916 Sunset Drive
 City of mailing address:: Raleigh
 State or Province of mailing address:: NC
 Country of mailing address:: US
 Postal or Zip Code of mailing address:: 27608

Correspondence Information

Correspondence Customer Number:: 00826

Representative Information

Representative Customer Number:: 00826

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This Application	National Stage of	PCT/US2004/011965	04/16/04

Foreign Priority Information

Country::	Application Number::	Filing Date::	Priority Claimed::
US	10/675,011	9/30/2003	YES

Assignee Information

Assignee name::	Biolex, Inc.
Street of mailing address::	158 Credle Street
City of mailing address::	Pittsboro
State or Province of mailing address::	NC
Country of mailing address::	US
Postal or Zip Code of mailing address::	27312

RTA01/2201565v1